Peer Review Process
Mathews Open Access Journals follows double blind peer review process. In this we do not reveal author names, affiliations to the reviewer and vice versa. We adhere to the Committee on Publication Ethics (COPE), code of conduct, and best practice guidelines (http://publicationethics.org). We strive to ensure that the peer review is fair, unbiased and timely. Decisions to accept or reject a manuscript for publication in the journal are based on the manuscript’s importance, originality, clarity, and the study’s validity and its relevance to remit of the journal. The process also involves strictly no plagiarism or fabrication of the data and parallel submissions.
Responsibilities
Being a reviewer you are accountable to take the responsibility of maintaining confidentiality of ideas that have been presented in the papers assigned to review. Focus your evaluation on merits and demerits of the article; assess the correctness, accuracy, clarity, and innovation of the research. Never reveal the assigned paper's results or videos/images or any of the supplementary material to non-reviewers.
The reviewers are given ample time for the review and submission of comments to the editorial office. Reviewers’ evaluations play a major role in our decision as to whether to accept a manuscript for publication.
Ethical Issues
Published : 01st April 2024
Author : Marjan Dzeparoski1,2,*
Citation : Dzeparoski M. (2024). Regulatory Update on eSubmissions in Balkans. Mathews J Pharma Sci. 8(1):26.
Published : 11th December 2023
Authors : Aria Hajihassan1, Atena Zandi1, Ghazal Esmaeili1, Mostafa Norizadeh2,3,*
Citation : Hajihassan A, et al. (2023). Investigating the Potential of Nilotinib and its Derivatives in Targeting Tau Protein Hyperphosphorylation for Alzheimer's Disease Treatment. Mathews J Pharma Sci. 7(4):25.
Published : 25th November 2023
Authors : Qadeer Ahmed, Muhammad Talha, Umer Ishtiaq, Saba Khurshid, Kaif Akbar, Urwa Amir, Muhammad Rehan, Ovais Ullah Shirazi, Shahid Latif, Zunaira Akbar, Iram Batool, Ali Akhtar*, Samreen Fatima
Citation : Ahmed Q, et al. (2023). Quality of Life and Medication Adherence in Rheumatoid Arthritis Patients. Mathews J Pharma Sci. 7(4):24.
Published : 03rd November 2023
Authors : Dadier Antonio Arroyo1,2,*, Linda Atencio1, Jorge Pérez Velásquez3, María Camila Coronado1, Meribeth Henry4, Maria Alejandra Suarez2, Daniela Katerine Rivera2
Citation : Arroyo DA, et al. (2023). Desensitization in a Patient with Hypersensitivity to the Iodinated Contrast Medium Iopromide: A Clinical Case Report. Mathews J Pharma Sci. 7(3):23.
Published : 17th October 2023
Author : Raúl Isea*
Citation : Isea R. (2023). We Continue to Battle with Diseases that are Difficult to Diagnose and Cure in the 21st Century. Mathews J Pharma Sci. 7(3):22.
Published : 11th October 2023
Authors : Allen B Richon1,*, Merry Ambos Richon2
Citation : Richon AB, et al. (2023). Four-Week Safety and Acceptability Study of 15% Bromelain Topical Lotion: An Open Label, Non-Comparative, Triple-Arm Study. Mathews J Pharma Sci. 7(3):21.